Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE: EU Warns AstraZeneca Over Vaccine Delivery Delay

Mon, 25th Jan 2021 19:15

(Alliance News) - The EU issued an angry warning to pharmaceutical group AstraZeneca PLC on Monday over its unexpected delay in delivering millions of doses of its Covid-19 vaccine to the bloc.

The British-Swedish company's announcement "is not acceptable to the EU," EU Commissioner for health Stella Kyriakides said after a meeting of member state representatives and the firm.

"The EU will take any action required to protect its citizens and rights," she stressed.

Kyriakides did not elaborate on what action Brussels might take, but she said Brussels would propose a "transparency mechanism" to track shipments of vaccine exported from the EU to non-member countries.

The unusually blunt message underscored the threat facing the 27-nation EU as it tries to ramp up so far underpowered vaccination programmes as more contagious coronavirus variants threaten a looming third wave of the pandemic.

Last Friday, AstraZeneca said it would not meet its contractual delivery commitments to the EU because of unexplained "reduced yields" in its European supply chain.

That came a week after US group Pfizer Inc said it was also cutting early delivery volumes of its vaccine produced with German firm BioNTech SE.

Together, those announcements risk up-ending EU vaccination programmes that depend on people getting two jabs weeks apart. 

That would potentially trash European Commission chief Ursula von der Leyen's pledge made just a week ago to inoculate 70% of adults in the EU by the end of August.

The EU has currently authorised two vaccines for jabs: the BioNTech/Pfizer and Moderna Inc ones. 

By the end of this week it is poised to add the AstraZeneca vaccine, on the understanding that it would be already on hand and available for immediate roll-out.

Those vaccines, along with others also being vetted for marketing authorisation, were secured by the European Commission under advance purchase agreements on behalf of the EU and its 450 million residents.

Von der Leyen early Monday spoke with AstraZeneca's French CEO Pascal Soriot, and representatives EU member states held two meetings with the company to press for answers and a rapid solution meeting the contract terms.

"The answers of the company have not been satisfactory so far," Kyriakides said.

In a sign of distrust of the company she announced a move to have pharmaceutical companies notify EU authorities of vaccine exports out of the bloc, except for humanitarian deliveries.

"The Commission has today proposed to the 27 member states in the steering board that an export transparency mechanism will be put in place as soon as possible," she said.

She added: "The EU has pre-financed the development of the vaccine and its production and wants to see the return. The EU wants to know exactly which doses have been produced where by AstraZeneca so far, and if or to whom they have been delivered."

The only public statement by AstraZeneca on Monday was that Soriot was "pleased" to speak with von der Leyen and it "is doing everything it can to bring its vaccine to millions of Europeans as soon as possible".

In an effort to create enough time for vaccinations to protect the most vulnerable, the EU and various member states have increasingly restricted travel into the bloc and, for non-essential trips, within it.

On Monday, the European Commission urged further tightening of those rules, calling on member states to impose pre-trip PCR tests for all travellers allowed into the EU and quarantine on arrival if they came from zones where more-contagious virus variants were spreading.

It also recommended a heightened testing and quarantine regime, where possible, for essential travellers between – or even within – EU countries with high-risk areas classed as "deep red" by the European Centre for Disease Prevention and Control.

The EU Commissioner for justice, Didier Reynders, said the new variants with high infectivity – coming from former EU member Britain as well as South Africa and Brazil – meant "there is an urgent need to reduce the risk of travel-related infections to lessen the burden on overstretched healthcare systems".

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.